Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) Following Raised Guidance
Go back to Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) Following Raised Guidance| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 107.28 +0.79 (0.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $106.49 | 52 Week High | $18.39 | |||
| Open | $107.45 | 52 Week Low | $6.96 | |||
| Day High | $108.53 | P/E | N/A | |||
| Day Low | $106.87 | EPS | $-0.58 | |||
| Volume | 390,137 | |||||
